Insider Buying: Actuate Therapeutics, Inc. (NASDAQ:ACTU) Director Buys 71,428 Shares of Stock

Actuate Therapeutics, Inc. (NASDAQ:ACTU - Get Free Report) Director Equity Cof Lp Bios purchased 71,428 shares of the stock in a transaction on Friday, June 27th. The stock was acquired at an average cost of $7.00 per share, for a total transaction of $499,996.00. Following the acquisition, the director directly owned 196,428 shares in the company, valued at approximately $1,374,996. This trade represents a 57.14% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Actuate Therapeutics Stock Down 3.2%

Shares of NASDAQ ACTU traded down $0.22 during midday trading on Thursday, reaching $6.53. 53,986 shares of the company traded hands, compared to its average volume of 58,310. Actuate Therapeutics, Inc. has a 12 month low of $5.50 and a 12 month high of $11.99. The stock's 50-day simple moving average is $8.95 and its 200-day simple moving average is $8.27.

Actuate Therapeutics (NASDAQ:ACTU - Get Free Report) last announced its earnings results on Thursday, May 15th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.06).

Institutional Trading of Actuate Therapeutics

Large investors have recently made changes to their positions in the business. BIOS Capital Management LP bought a new position in shares of Actuate Therapeutics in the fourth quarter valued at about $78,753,000. Envestnet Asset Management Inc. acquired a new stake in Actuate Therapeutics in the 4th quarter valued at about $83,000. Mercer Global Advisors Inc. ADV acquired a new stake in Actuate Therapeutics in the 4th quarter valued at about $130,000. Voss Capital LP bought a new position in shares of Actuate Therapeutics in the fourth quarter worth about $440,000. Finally, Sigma Planning Corp acquired a new position in shares of Actuate Therapeutics during the fourth quarter worth approximately $128,000.

Analyst Upgrades and Downgrades

A number of brokerages have commented on ACTU. Craig Hallum initiated coverage on shares of Actuate Therapeutics in a research note on Tuesday, April 22nd. They set a "buy" rating and a $21.00 price target for the company. HC Wainwright increased their target price on Actuate Therapeutics to $20.00 and gave the stock a "buy" rating in a report on Tuesday, June 3rd.

Actuate Therapeutics Company Profile

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.